Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Windlas Biotech Ltd. ( (IN:WINDLAS) ).
Windlas Biotech Limited has secured shareholder approval via postal ballot for key board appointments, including the re-appointment of Ashok Kumar Windlass as whole-time director from May 3, 2026, and the appointment of Vivek Dhariwal and Gaurav Gulati as independent directors from May 6, 2026. The resolutions were passed with the requisite majority through a remote e-voting process concluded on March 19, 2026, underscoring the company’s adherence to corporate governance norms and signaling continuity and stability in its leadership structure for investors and other stakeholders.
The company has filed the scrutinizer’s report and detailed voting results with the stock exchanges in line with SEBI’s listing regulations. These voting outcomes and the scrutinizer’s report have also been published on the company’s website and that of its registrar, enhancing transparency around shareholder decision-making and regulatory compliance.
More about Windlas Biotech Ltd.
Windlas Biotech Limited is an India-based pharmaceutical and biotech company engaged in manufacturing and supplying formulations and related healthcare products. Listed on both BSE and NSE, the company serves domestic and international markets and operates from facilities in Dehradun and a corporate office in Gurgaon, with a focus on regulated governance and compliance with securities regulations.
Average Trading Volume: 2,046
Technical Sentiment Signal: Sell
Current Market Cap: 15.17B INR
For detailed information about WINDLAS stock, go to TipRanks’ Stock Analysis page.